How optimized LLMs are transforming drug development
March 26th, 10 am PT | 1 PM ET
Register now
Large Language Models (LLMs) are transforming drug development by accelerating research, improving decision-making, and enhancing efficiencies across various process stages. However, to fully harness their potential, LLMs must be optimized for specific use cases and tailored to the unique needs of pharmaceutical organizations.
Join us on March 26th to discover how optimized LLMs can transform drug discovery, clinical trials, and regulatory processes by:
- Reduce time to market by streamlining research and data analysis
- Improve accuracy and compliance through tailored AI models
- Enhance collaboration across research, clinical, and regulatory teams
You’ll learn best practices for integrating LLMs into pharmaceutical workflows, ensuring compliance with regulatory frameworks, and optimizing AI models to drive innovation. Discover how leading organizations are leveraging AI to gain a competitive edge while maintaining efficiency and compliance.
Featured Speakers
Chris McSpiritt
VP, Life Sciences Strategy
Christopher McSpiritt is a seasoned business architect, consultant, and product leader who has spent almost two decades specializing in helping life sciences organizations improve drug development processes through process reengineering efforts and the deployment of innovative software/analytics solutions. As VP of Life Sciences Strategy at Domino Data Lab, he leads Domino's go-to-market and product strategy for the pharmaceutical industry.